Asian Spectator

Men's Weekly

.

TÜV SÜD Appoints Interim Leadership Following CEO Transition

MUNICH, GERMANY – NEWSAKTUELL - 10 July 2025 - The Supervisory Board of TÜV SÜD AG has appointed Ishan Palit, former Asia Pacific CEO, as Interim Chief Executive Officer (Chairman of ...

Wirecard Brings Its Platform Services Around Digital Financial...

ASCHHEIM, Germany and SYDNEY, November 5, 2018, /PRNewswire-AsiaNet/-- - Wirecard is now offering omnichannel solutions in Australia and e-commerce services in New Zealand - Wirecard is leve...

Understanding Vitiligo, A Little-Understood Skin Condition

SINGAPORE - Media OutReach - 25 June 2019 - For the past eight years, June 25 has been designated as World Vitiligo Day to help increase awareness of a skin disease known...

Cappfinity and Lexxic Partnership Helps Organisations Embrace ...

LONDON, March 9, 2022, /PRNewswire-AsiaNet/-- HR tech firm, Cappfinity, has announced a new partnership with specialist neurodiversity consultancy, Lexxic, to help businesses create a cultur...

Madame Tussauds Hong Kong Kicks Off 2018 with Angelababy

HONG KONG, CHINA - Media OutReach - 30 November 2017 - Madame Tussauds Hong Kong announced that Angelababy (Yeung Wing) will join other Fashion celebrities and become the first female artist...

Aramco, top F1 team kindle racing enthusiasm among middle school students in Shanghai

SHANGHAI, CHINA - Media OutReach Newswire - 23 April 2024 - Aramco and Aston Martin Aramco Formula One Team have jointly launched the "Make A Mark" initiative in Shanghai. The event invites...

JA Solar Recognized as "Top Performer" in DNV GL/PVEL 2019 PV ...

BEIJING, June 28, 2019 /PRNewswire-AsiaNet/-- JA Solar Co., Ltd, a world-leading manufacturer of high-performance photovoltaic products, announced that it has been recognized as "Top Perform...

Cognigy Named a Leader in IDC MarketScape for General-Purpose ...

DÜSSELDORF, Germany and SAN FRANCISCO and SYDNEY, Oct. 9, 2021 /PRNewswire-AsiaNet/ -- - Cognigy has been recognized as a Leader in the IDC MarketScape: Worldwide General-Purpose Conver...

Product Analytics Leader Mixpanel Secures $200 Million Growth ...

SAN FRANCISCO and BOSTON, Nov. 16, 2021 /PRNewswire-AsiaNet/-- --Investment from Bain Capital Tech Opportunities Values Mixpanel at Over $1 Billion; Funding Will Drive Product-led Growth Str...

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

HONG KONG, May 26, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug (generic name: Penpulimab; R&D code: AK105) jointly developed and commercialized with Akeso, Inc. (HKEX: 9926), a biopharmaceutical company committed to R&D, production and commercialization of affordable innovative antibody drugs for patients worldwide, has been accepted by the National Medical Products Administration of the PRC, for the treatment of patients with relapsed or refractory Classical Hodgkin's Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age . cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%. Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment .

Professor Zhu Jun, Co-principal investigator of the lead unit Beijing Cancer Hospital is full of expectations for such a differentiated anti PD-1 monoclonal product and said, through bioengineering technology, Penpulimab completely eliminate the binding activity of Fc receptors and avoid the antibody-dependent cell-mediated cytotoxicity (ADCC) effect. At the same time, compared with other drugs available in the market working on the same target, it has a slower rate of antigen binding and dissociation, which makes the biological effect stronger and improves its anti-tumor activity.

Co-lead researcher Professor Song Yuqin, Director of Lymphoma Department at Peking University Cancer Hospital said, in clinical trial, Penpulimab was observed with gratifying therapeutic data and good safety. As a clinician, Professor Song hoped that Penpulimab can be launched to the market soon, which will benefit more patients and their families.

About Sino Biopharmaceutical Limited (HKEX: 1177)Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng Index - Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index - Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018. http://www.sinobiopharm.com/.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Diplomasi emosional: Bagaimana rasa marah dan takut dapat membentuk arah kebijakan global

Gambar Perdana Menteri Israel Benjamin Netanyahu (kiri) dan Pemimpin Tertinggi Iran Ayatollah Ali Khamenei di layar, merefleksikan perang antara Iran dan Israel.Mmiss.cabul/Shutterstock● Memanas...

Riset: Populasi hewan langka anoa dan babirusa di pulau kecil lebih tangguh, meski jumlahnya sedikit

● Populasi satwa di pulau kecil terbukti lebih tangguh secara genetik meski jumlahnya sedikit.● Pulau kecil dapat menjadi habitat alami yang penting bagi kelangsungan hewan langka.● ...

6 bulan Makan Bergizi Gratis: Program kesehatan atau bantuan sosial?

Program Makan Bergizi Gratis (MBG) jadi program mercusuar pemerintahan Prabowo-Gibran yang sudah berlangsung selama lebih dari enam bulan. Inisiatif ini menyasar kelompok-kelompok yang rentan mengalam...